GSK plc (LSE/NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.

葛兰素史克公司（LSE/NYSE：GSK）和生物平台创新公司 Flagship Pioneering（Flagship）今天宣布，双方已开始合作，目标是从呼吸和免疫学领域入手，发现和开发一系列未来变革性药物和疫苗。

This alliance brings together GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.

该联盟将葛兰素史克在疾病领域的专业知识和发展能力与旗舰生物平台公司的生态系统结合在一起，包括其新颖的模式和技术，以在医疗保健方面取得重大进展。

GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship’s bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development.

葛兰素史克（GSK）和旗舰（Flagship）最初将提供高达1.5亿美元的前期资金，用于支持探索阶段，以确定最有希望的概念，以便与旗舰（Flagship）的生物平台公司进行进一步的研究和开发。通过这些探索，该合作旨在确定多达10种新药和疫苗的组合，每种药物和疫苗都将由葛兰素史克独家选择用于进一步的临床开发。

Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme.

根据协议条款，Flagship 及其生物平台公司将有资格从葛兰素史克公司获得高达 7.2 亿美元的预付款、开发和商业里程碑，以及每个收购项目的临床前资金和分级特许权使用费。

Tony Wood, Chief Scientific Officer, GSK, said: “Together with Flagship, we will use science and technology to deliver best-in-class innovation at pace. We look forward to partnering with the talented team at Flagship, and their ecosystem of bioplatform companies, to further accelerate our pipeline and discover practice-changing medicines and vaccines for patients.”.

葛兰素史克（GSK）首席科学官托尼·伍德（Tony Wood）表示：“我们将与旗舰公司（Flagship）一起，利用科学技术，以最快的速度实现一流的创新。我们期待着与旗舰公司（Flagship）的人才团队及其生物平台公司生态系统合作，以进一步加快我们的流程，并为患者发现改变实践的药物和疫苗。”。

Paul Biondi, General Partner, Flagship Pioneering and President, Pioneering Medicines, said: “Flagship and GSK have a shared focus on delivering breakthrough medicines for patients. This collaboration is the latest example of Flagship’s Innovation Supply Chain Partnership model, which is designed to generate transformational medicines together with our pharma partners by leveraging our ecosystem of first-in-category bioplatforms to create a sustainable source of treatments for patients with the greatest unmet needs.”.

旗舰创业公司普通合伙人兼总裁保罗·比昂迪（Paul Biondi）表示：“旗舰公司和葛兰素史克（GSK）共同致力于为患者提供突破性药物。此次合作是旗舰公司创新供应链伙伴关系模式的最新例子，该模式旨在通过利用我们一流的生物平台生态系统，与我们的制药合作伙伴一起产生变革性药物，为最大未满足需求的患者创造可持续的治疗来源。”。

About Flagship Pioneering

关于Flagship Pioneering

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value.

Flagship Pioneering发明并建立生物平台公司，每个公司都有潜力开发多种产品，改变人类健康或可持续发展。自2000年推出以来，Flagship已经发起并培育了100多家科学企业，总价值超过750亿美元。

To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture,  and Tessera Therapeutics..

迄今为止，Flagship已经部署了超过38亿美元的资本，用于开创性公司的成立和发展，以及其他机构超过270亿美元的后续投资。目前的旗舰生态系统由40家公司组成，包括‡Foghorn Therapeutics‡（纳斯达克：FHTX），Moderna‡（纳斯达克：MRNA），Omega Therapeutics（纳斯达克：OMGA），‡Sana Biotechnology‡（纳斯达克：Sana），‡Generate Biomedicines，‡Inari，‡Indigo Agriculture，‡和‡Tessera Therapeutics。。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性生物制药公司，旨在将科学、技术和人才团结起来，共同战胜疾病。更多信息请访问gsk.com。